TY - JOUR
T1 - Cardiovascular risk management in gout patients
T2 - do patients benefit from screening in secondary care?
AU - Vedder, Daisy
AU - Heslinga, Maaike
AU - Wijbrandts, Carla A.
AU - Nurmohamed, Michael T.
AU - Gerritsen, Martijn
N1 - Funding Information: Funding: the ‘Reade Gout Cohort’ received partial funding from Grunenthal. Competing interests: none declared. Funding Information: We are grateful to all patients participating in the ‘Reade Gout cohort’ and all rheumatologists from Reade Amsterdam for the recruitment. We would also like to thank Grunenthal for financial supporting this cohort. Publisher Copyright: © Copyright Clinical and Experimental Rheumatology 2023.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Objective To estimate the 10-year cardiovascular disease (CVD) risk in gout patients in secondary care and to evaluate the effect of CVD risk screening on the 10-year CVD risk after 1 year. Methods A prospective cohort study was performed in patients with gout from Reade Amsterdam. Data on gout and CVD history, traditional risk factors, medication, and lifestyle were collected at baseline and 1 year. The 10-year CVD risk was calculated with the use of the NL-SCORE. A paired sample t-test and McNemar test was performed to test for differences between baseline and the 1-year visit. Results A very high prevalence of traditional CV risk factors was seen in our secondary care gout patients. Nineteen percent without previous CVD were categorised in the high-risk group according the NL-SCORE. The prevalence of CVD increased from 16% to 21% after 1-year follow-up. A decrease was seen in total- and LDL-cholesterol after 1 year. No decrease in mean BMI, waist-hip ratio, blood pressure or NL-SCORE was observed. Conclusion The current need for CVD risk screening of gout patients in secondary care was illustrated by the high prevalence of traditional risk factors in this cohort. Recommendations to patients and the general practitioner (GP) alone did not result in overall improvement of traditional CVD risk factors nor the 10-year CVD risk. Our results indicate that a more prominent role of the rheumatologist is necessary to optimise the process of initiation and management of CVD risk in gout patients.
AB - Objective To estimate the 10-year cardiovascular disease (CVD) risk in gout patients in secondary care and to evaluate the effect of CVD risk screening on the 10-year CVD risk after 1 year. Methods A prospective cohort study was performed in patients with gout from Reade Amsterdam. Data on gout and CVD history, traditional risk factors, medication, and lifestyle were collected at baseline and 1 year. The 10-year CVD risk was calculated with the use of the NL-SCORE. A paired sample t-test and McNemar test was performed to test for differences between baseline and the 1-year visit. Results A very high prevalence of traditional CV risk factors was seen in our secondary care gout patients. Nineteen percent without previous CVD were categorised in the high-risk group according the NL-SCORE. The prevalence of CVD increased from 16% to 21% after 1-year follow-up. A decrease was seen in total- and LDL-cholesterol after 1 year. No decrease in mean BMI, waist-hip ratio, blood pressure or NL-SCORE was observed. Conclusion The current need for CVD risk screening of gout patients in secondary care was illustrated by the high prevalence of traditional risk factors in this cohort. Recommendations to patients and the general practitioner (GP) alone did not result in overall improvement of traditional CVD risk factors nor the 10-year CVD risk. Our results indicate that a more prominent role of the rheumatologist is necessary to optimise the process of initiation and management of CVD risk in gout patients.
KW - CV risk management
KW - cardiovascular risk
KW - gout
KW - secondary care
UR - http://www.scopus.com/inward/record.url?scp=85168797040&partnerID=8YFLogxK
U2 - https://doi.org/10.55563/clinexprheumatol/38fbvd
DO - https://doi.org/10.55563/clinexprheumatol/38fbvd
M3 - Article
C2 - 37279144
SN - 0392-856X
VL - 41
SP - 1762
EP - 1767
JO - Clinical and experimental rheumatology
JF - Clinical and experimental rheumatology
IS - 9
ER -